ADVM

Adverum Biotechnologies, Inc.

0.94 USD
-0.07 (-6.93%)
Last updated
This page is just a preview of the data found in TrendSpider’s full version

Adverum Biotechnologies, Inc. stock is up 2.17% since 30 days ago. The next earnings date is Mar 28, 2024. The company has had below-average volume in the last 30 days. Its seasonality going into this month shows a chance of a green month, as 62.5% of the previous 7 December’s closed higher than November.

About Adverum Biotechnologies, Inc.

Adverum Biotechnologies, Inc. develops gene therapy product candidates to treat ocular and rare diseases. Its lead product candidate is ADVM-022, a single intravitreal injection gene therapy candidate. The company was incorporated in 2006 and is headquartered in Redwood City, California.